CancerAdultAgedFemaleHumansMale
Optimized dose schedule of rucaparib and liposomal irinotecan/5-fluorouracil in metastatic gastrointestinal cancers: A phase 1 study.
Cody Eslinger, Daniel Walden, Alexandra Krivonos, Numrah Fadra, Tyler Zemla, Wen Wee Ma, Bassel El-Rayes, Olatunji Alese, Thorvardur Halfdanarson, Timothy Hobday, Sarah Bruggeman, Brandy Jaszewski, Fang-Shu Ou, Mohamad Bassam Sonbol, Daniel Ahn
Published: 202510.1002/cncr.70184
Abstract
BACKGROUND: This phase 1 study aimed to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary efficacy of rucaparib (RUB), a poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor, combined with liposomal irinotec…
Preview only. Read the full abstract at the source